Tislelizumab
- Generic Name
- Tislelizumab
- Brand Names
- Tevimbra, Tizveni
- Drug Type
- Biotech
- Chemical Formula
- -
- CAS Number
- 1858168-59-8
- Unique Ingredient Identifier
- 0KVO411B3N
- Background
Tislelizumab is under investigation in clinical trial NCT02660034 (The Safety, Pharmacokinetics and Antitumor Activity of BGB-A317 in Combination With BGB-290 in Subjects With Advanced Solid Tumors).
- Indication
⑴用于治疗至少经过二线系统化疗的复发或难治性经典型霍奇金淋巴瘤（R/R cHL）患者。
⑵用于治疗局部晚期或转移性尿路上皮癌。
⑶联合化疗用于治疗一线晚期非鳞状非小细胞肺癌（NSCLC）患者。
⑷用于治疗既往接受过治疗的不可切除肝细胞癌患者。
⑸用于治疗晚期恶性实体瘤
- Associated Conditions
- -
- Associated Therapies
- -
Tislelizumab Combined With Chemotherapy or Radiotherapy in the Treatment of Advanced or Recurrent Metastatic Elderly Esophageal Cancer
- Conditions
- Interventions
- First Posted Date
- 2022-11-28
- Last Posted Date
- 2024-08-13
- Lead Sponsor
- Fujian Cancer Hospital
- Target Recruit Count
- 130
- Registration Number
- NCT05628610
Testing Immunotherapy for Patients With Liver Cancer and Moderately Altered Liver Functions
- First Posted Date
- 2022-11-18
- Last Posted Date
- 2024-09-30
- Lead Sponsor
- UNICANCER
- Target Recruit Count
- 50
- Registration Number
- NCT05622071
- Locations
- 🇫🇷
Hôpital Avicenne, Bobigny, France
🇫🇷Hôpital Michallon, Grenoble, France
🇫🇷Institut Paoli Calmette, Marseille, France
Tislelizumab in Combination With Sitravatinib for Recurrent/Metastatic Cervical Cancer After Platinum-Based Chemotherapy
- Conditions
- Interventions
Neoadjuvant of Tislelizumab Combined With Chemotherapy Followed by Surgery in Unresectable Stage Ⅲ NSCLC
- Conditions
- Interventions
- First Posted Date
- 2022-11-10
- Last Posted Date
- 2023-12-29
- Lead Sponsor
- Beijing Tsinghua Chang Gung Hospital
- Target Recruit Count
- 30
- Registration Number
- NCT05611879
- Locations
- 🇨🇳
Beijing Tsinghua Chang Gung Hospital, Beijing, Beijing, China
A Study Investigating the Efficacy and Safety of LBL-007 Plus Tislelizumab in Combination With Bevacizumab Plus Fluoropyrimidine Versus Bevacizumab Plus Fluoropyrimidine in Participants With Unresectable or Metastatic Colorectal Cancer
- First Posted Date
- 2022-11-08
- Last Posted Date
- 2024-10-28
- Lead Sponsor
- BeiGene
- Target Recruit Count
- 226
- Registration Number
- NCT05609370
- Locations
- 🇺🇸
Usc Norris Comprehensive Cancer Center (Nccc), Los Angeles, California, United States
🇺🇸Ut Health San Antonio Mays Cancer Center, San Antonio, Texas, United States
🇨🇳Nanyang Central Hospital, Nanyang, Henan, China
A Neoadjuvant Study of Tislelizumab and SX-682 for Resectable Pancreas Cancer
- First Posted Date
- 2022-11-03
- Last Posted Date
- 2024-03-15
- Target Recruit Count
- 25
- Registration Number
- NCT05604560
- Locations
- 🇺🇸
Johns Hopkins SKCCC, Baltimore, Maryland, United States
Patient-reported Outcomes in Preoperative Immunochemotherapy/Radiotherapy-treated Esophageal Cancer Patients
- First Posted Date
- 2022-10-27
- Last Posted Date
- 2022-11-28
- Lead Sponsor
- Guangdong Provincial People's Hospital
- Target Recruit Count
- 50
- Registration Number
- NCT05596890
- Locations
- 🇨🇳
Guangdong Provincial People's Hospital, Guangzhou, Guangdong, China
Radiotherapy With Tislelizumab in Patients With Recurrent Head & Neck Cancer
- Conditions
- Interventions
- First Posted Date
- 2022-10-27
- Last Posted Date
- 2022-10-27
- Target Recruit Count
- 20
- Registration Number
- NCT05595590
- Locations
- 🇨🇳
Sichuan Cancer Hosiptal, Chengdu, Sichuan, China
🇨🇳Tianjin Medical University Cancer Institute and Hospital, Tianjin, Tianjin, China
Tislelizumab Combined With Concurrent Chemoradiotherapy for Locally Advanced Cervical Cancer
- Conditions
- Interventions
- First Posted Date
- 2022-10-20
- Last Posted Date
- 2023-11-24
- Lead Sponsor
- Yong Zhang,MD
- Target Recruit Count
- 30
- Registration Number
- NCT05588219
- Locations
- 🇨🇳
First Affiliated Hospital of Guangxi Medical University, Nanning, Guangxi, China
First-line Treatment With RC48 Plus Tislelizumab and S-1(RCTS) in Advanced Gastric Cancer
- Conditions
- Interventions
- First Posted Date
- 2022-10-19
- Last Posted Date
- 2022-10-19
- Lead Sponsor
- Qilu Hospital of Shandong University
- Target Recruit Count
- 55
- Registration Number
- NCT05586061
- Locations
- 🇨🇳
Central Hospital Affiliated to Shandong First Medical University, Jinan, Shandong, China
🇨🇳Shandong Provincial Hospital Affiliated to Shandong First Medical Universiry, Jinan, Shandong, China
🇨🇳The First Affiliated Hospital of Shandong First Medical University (Shandong Provincial Qianfoshan Hospital), Jinan, Shandong, China
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.